Organisation paid for research Program year 2024 Source: CMS Open Payments

Ellipsis Group

Neither a doctor nor a teaching hospital

Research payments

$778,835

833 payments

Through program year 2024, Ellipsis Group is reported as receiving $778,835 in research payments, across 833 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$2,464	1
2023	Research	$58,524	24
2022	Research	$60,916	66
2021	Research	$75,918	167
2020	Research	$212,082	389
2019	Research	$368,931	186

Breakdown

Who paid Research payments · program years 2019–2024

Novo Nordisk AS $678,884 816 payments
Novartis Pharmaceuticals Corporation $66,117 5 payments
Pfizer Inc. $20,387 8 payments
Ironwood Pharmaceuticals, Inc $9,938 2 payments
GlaxoSmithKline, LLC. $3,509 2 payments

Studies the money was for Research payments · program years 2019–2024

Ex9536-4388 $200,441 282 payments
Nn9536-4376 $144,319 33 payments
Nn9536-4374 $140,228 53 payments
Ex9924-4473 $103,070 262 payments
An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $54,028 3 payments
Nn9535-4321 $39,739 137 payments
Nn9924-4280 $25,498 2 payments
Nn9535-4506 $21,411 45 payments
A 16Week Phase 2 Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin $14,576 4 payments
A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $12,089 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.